

**ANTI-ARTHRITIC ACTIVITY OF A HERBAL FORMULATION  
(JOINTEEZ) IN ALBINO WISTAR RATS**

**ABSTRACT**

**Aim:** This study evaluated the anti-arthritis activity of a herbal formulation used in the management of rheumatoid arthritis in Nigeria.

**Design:** Thirty-five (35) albino wistar rats were used. They were divided into seven groups of seven rats each, with Group A serving as negative control while Group B was the positive control. Groups B, C, D and E were induced with rheumatoid arthritis by injecting 0.1ml of Complete Freund's Adjuvant into the right hind paw of each rat. The rats were treated with the standard drug and herbal formulation respectively for 28 days as follows: Group C (treated with a standard drug, Celebrex), Group D (treated with the herbal drug, Jointeez), Group E (treated with a combination therapy of Jointeez and Celebrex). At the end of the 28-day treatment period, the rats were anaesthetized with chloroform and sacrificed through puncture of the jugular vein. Five millilitres (5ml) of blood samples were put into plain bottles for the analysis of biochemical parameters.

**Place and duration of study:** This study was conducted in the Department of Medical Laboratory Science, Rivers State University, from September to December, 2018.

**Methodology:** The inflammatory markers, **tumour necrosis factor alpha** (TNF- $\alpha$ ), **interleukin 6** (IL-6) and C-reactive protein, were analysed using ELISA technique.

**Results:** The levels of TNF- $\alpha$  ( $p < 0.001$ ), IL-6 ( $p = 0.01$ ) and C-reactive protein ( $p < 0.001$ ) were significantly reduced in the treated rats compared to the positive control group. There were significant reduction in the paw diameters of the treated rats ( $p < 0.001$ ). The combination therapy used in this study did not offer significantly different therapeutic advantage over the monotherapies used in this study. The herbal formulation used in this study offered similar therapeutic activities as the orthodox drug used in this study.

**Conclusion:** The herbal formulations can be used as safe therapies for the management of rheumatoid arthritis in our population. It is recommended that herbal formulations be integrated into our healthcare system in the management of rheumatoid arthritis.

**KEYWORDS:** Herbal formulation, Complete Freund's Adjuvant, Rheumatoid Arthritis, Nigeria

**INTRODUCTION**

Rheumatoid arthritis is a chronic, autoimmune disease that affects the joints and also has extra-articular as well as systemic manifestations<sup>1</sup>. Rheumatoid arthritis causes severe pain, swelling, early morning stiffness of the joint, and often there may be loss of function<sup>2</sup>.

39 The aetiology of rheumatoid arthritis is not known, but some factors have been reported to be the  
40 likely causative or predisposing factors. These include genetic, environmental and hormonal  
41 factors<sup>3</sup>. The Genome Wide Association Studies (GWAS) have enabled researchers to identify  
42 the genetic risk factors for many human diseases including rheumatoid arthritis. The greatest  
43 risk of the disease lies within the HLA (Human Leukocyte Antigen) region which codes for HLA  
44 – DRB1 \*04 molecule<sup>4</sup>. HLA – DRB1 \* 01 and HLA – DRB1 \*04 have been associated with  
45 the susceptibility of individuals to rheumatoid arthritis<sup>5</sup>. Similarly, non-HLA genes have been  
46 associated with rheumatoid arthritis. Single nucleotide polymorphisms in PTPN22, IL23R,  
47 TRAF1, CTLA4 and others have been linked with the pathogenesis of rheumatoid arthritis<sup>6</sup>.

48  
49 Environmental risk factors are also known to predispose to rheumatoid arthritis. The strongest  
50 known of these environmental factors is smoking. This risk is higher in predisposed individuals  
51 who are anti-citrullinated peptide antibody (ACPA) – positive or rheumatoid factor – positive<sup>7</sup>.  
52 This gene-environment interaction further increases the risk by the number of shared epitopes.  
53 The shared epitope refers to a sequence of amino acids on the HLA – DRB1 allele<sup>7</sup>. It has been  
54 reported that smoking accounts for about 20 – 30% of environmental risks of rheumatoid  
55 arthritis<sup>8</sup>. Another environmental risk factor is exposure to silica or industrial dust<sup>7</sup>.

56 There is a growing popularity of **complementary and alternative medicine** (CAM) among the  
57 general population. In many developed countries, about 70 – 80% of the population use CAM<sup>9</sup>.  
58 In spite of this, phytotherapeutics, or the use of herbs for medicines has not been accepted into  
59 mainstream healthcare delivery, probably due to lack of knowledge by orthodox practitioner<sup>10</sup>.

60 It is known that many human diseases have been treated using herbal remedies all through  
61 human history<sup>11</sup>. Thus, it is possible to discover new, effective and more affordable drugs for the

62 treatment of human diseases<sup>12</sup>. Herbal formulations are being used for improving health and for  
63 the treatment or prevention of human diseases<sup>13</sup>. This widespread acceptance and use can be  
64 attributed to the notion that herbal medicines are generally safe and non-toxic<sup>14</sup>. This is more so  
65 as it has been reported that about 80% of hospital admissions in the United States of America  
66 alone are due to the toxicity of synthetic drugs<sup>15</sup>.

67 The renewed and growing interest of the world population for use of alternative medicines is  
68 predicated on several factors. Some of these factors include high cost and side effects of  
69 orthodox drugs amongst other factors<sup>16</sup>. In the case of rheumatoid arthritis, the drugs used for its  
70 treatment have been reported to cause a number of safety and efficacy problems. Some of the  
71 side effects of conventional anti-arthritis drugs include stomatitis, myelosuppression (common  
72 with DMARDs like methotrexate), GIT problems, renal problems, haematological abnormalities  
73 (common with NSAIDs)<sup>17</sup>. The effort to search for affordable and safer alternatives for these  
74 conventional drugs is the major driving force for the increased interests in the use of herbal  
75 formulations<sup>18</sup>.

76 **The aim of this study is to evaluate the anti-arthritis activity of Jointeez used in the management**  
77 **of rheumatoid arthritis.**

78

## 79 **MATERIALS AND METHODS**

### 80 **Experimental Animals**

81 Thirty-five (35) female Albino Wistar rats, weighing 150-200g were used for this study.

82 The rats were housed in compartmentalized cage and allowed to acclimatize for two weeks, in a  
83 daily 12-hourly light and dark cycle. They were allowed access to standard feed and water *ad*  
84 *libitum*.

### 85 **Experimental Drugs**

86 The standard drug used for this study was Celebrex (Celecoxib), a product of Pfizer  
87 Pharmaceuticals, Puerto Rico. The used herbal formulation used for this study was Jointeez  
88 (product of Kedi Healthcare Industries Limited, Nigeria). **The ingredients of Jointeez include**  
89 **Radix aconite preparata (Chuanwu), Radix aconiti kusnezoffii preparata (Caowu), Flos carthami**  
90 **(Honghua), Glycyrrhiza uralensis fisch (Gancao) and Fructus chaenomelis (Mugua).**

91

### 92 **Determination of Therapeutic Doses**

93 The rat doses of the herbal formulations and orthodox drugs were extrapolated from the human  
94 therapeutic doses based on body surface area ratio, using the Paget and Barnes (1964)<sup>19</sup>  
95 conversion table.

96 The daily dose of both the standard drug and the herbal formulations were determined based on  
97 OECD's Guidelines (OECD, 2001)<sup>20</sup>.

98

### 99 **Acute Toxicity Testing of the Herbal Drugs**

100 This was done using the Fixed Dose Procedure (OECD, 2001).

101 Three rats were put in a cage, fasted overnight, and then given 2000mg/kg of

102 Jointeez. They were observed for three days for signs of toxicity of the drugs.

### 103 **Experimental Design**

104 Thirty-five (35) rats were put into seven (7) groups of seven (7) rats each as follows:

- 105 a) Group A was not induced, and served as negative control group.
- 106 b) Group B was induced with rheumatoid arthritis using Complete Freund's Adjuvant, and  
107 given distilled water. This was the positive control group.
- 108 c) Group C was induced with rheumatoid arthritis using Complete Freund's Adjuvant, and  
109 treated with 36mg/kg body weight of the standard drug, Celecoxib (commonly known as  
110 Celebrex).
- 111 d) Group D was induced with rheumatoid arthritis using Complete Freund's Adjuvant, and  
112 treated with 126mg/kg body weight of Jointeez
- 113 e) Group F was induced with rheumatoid arthritis using Complete Freund's Adjuvant and  
114 treated with a combination therapy of Jointeez and Celebrex at therapeutic doses

115

### 116 **Induction of Rheumatoid Arthritis**

117 Rheumatoid arthritis was induced in the rats in groups B, C, D, and E, using 0.1ml (100µl) of  
118 Complete Freund's Adjuvant (CFA). This induction was done using the method of <sup>21</sup>. Briefly,  
119 each rat was given 0.1ml of the adjuvant in the subplantar region of the right foot and observed  
120 for 14 days before commencement of therapy.

121 The paw diameter of the induced rats was measured using Vernier Calipers before the induction,  
122 and once every week during the period of the study. The dorsoventral area of the paw was  
123 measured according to the method of <sup>22</sup>.

## 124 **Treatment**

125 The rats that were induced with rheumatoid arthritis were treated for four (4) weeks after  
126 induction of the arthritis. The treatment, using the herbal formulations and the standard drugs,  
127 was given by oral gavage once daily for four weeks.

128

## 129 **3.8 Morphological Assessment**

130 The morphological assessment (arthritis score) was done using the method of <sup>23</sup>. Briefly, scoring  
131 for morphological assessment was done as follows:

132 Normal paw = 0, mild swelling and erythema of digits = 1, moderate swelling and erythema of  
133 digits = 2, severe swelling and erythema = 3, gross deformity and inability to use limbs = 4. The  
134 maximum score for both paws is 8

135 The morphological assessment was done once weekly for the duration of study.

## 136 **Sample Collection**

137 The rats were sacrificed after an overnight fast. They were anaesthetized using chloroform.  
138 Blood samples were collected by puncture of the jugular vein and put into plain bottles for the  
139 analysis of TNF- $\alpha$ , IL-6 and C- reactive protein.

140 **The knee of the right hind paw of rats from each group were harvested for histological analysis.**

## 141 **Laboratory Analysis**

142 TNF- $\alpha$ , IL-6 and C-reactive protein were assayed using ELISA technique

143

## 144 **Data Analysis**

145 Data from this study were analyzed using SPSS version 23. P-values less than 0.05 were  
146 considered statistically significant in this study.

## 147 **RESULTS**

### 148 **4.1 Acute Toxicity Study**

149 The result of the acute toxicity study of the herbal drug shows that there was no mortality or any  
150 sign of toxicity observed after three days of administration of the herbal formulation. The herbal  
151 formulation was therefore considered safe and non-toxic up to 2000mg/kg body weight.

### 152 **4.2 Biochemical Parameters**

153 The results of the biochemical parameters are as shown in the table below:

154 **Table 1: Mean  $\pm$  SD of Biochemical Parameters**

Groups	TNF- $\alpha$ (pg/ml)	CRP (ng/ml)	IL-6 (pg/ml)
Group A (NC)	13.96 $\pm$ 2.58 <sup>a</sup>	217.73 $\pm$ 8.08 <sup>a</sup>	7.32 $\pm$ 0.30 <sup>a</sup>
Group B (PC)	20.15 $\pm$ 0.92 <sup>b</sup>	251.72 $\pm$ 15.34 <sup>b</sup>	11.31 $\pm$ 2.74 <sup>b</sup>
Group C (CB)	15.67 $\pm$ 2.49 <sup>a</sup>	214.35 $\pm$ 25.36 <sup>a</sup>	6.75 $\pm$ 1.32 <sup>a</sup>
Group D (JZ)	16.61 $\pm$ 0.72 <sup>a</sup>	216.62 $\pm$ 17.39 <sup>a</sup>	7.15 $\pm$ 1.66 <sup>a</sup>
Group E (CB + JZ)	15.18 $\pm$ 3.21 <sup>a</sup>	213.44 $\pm$ 9.34 <sup>a</sup>	6.80 $\pm$ 0.98 <sup>a</sup>
<i>p</i> -value	< .001	< .001	0.010
F-value	7.840	6.956	4.124

155 ANOVA, followed by Tukey's multiple comparison.

156 a = significantly different compared with positive control ( $p < 0.05$ )

157 b = significantly different compared with negative control ( $p < 0.05$ )

158

159

160

### 161 4.3 Paw Volume of Rats

162 The changes in the paw diameters are as shown in the table below:

163

164 **Table 2: Mean  $\pm$  SD of Paw Volume of Rats**

165

	Group A	Group B	Group C	Group D	Group E
Week 1	0.36 $\pm$ 0.05	0.60 $\pm$ 0.07	0.72 $\pm$ 0.05	0.70 $\pm$ 0.06	0.67 $\pm$ 0.08
Week 2	0.36 $\pm$ 0.05 <sup>a</sup>	0.61 $\pm$ 0.07 <sup>a</sup>	0.69 $\pm$ 0.07 <sup>b</sup>	0.65 $\pm$ 0.10 <sup>b</sup>	0.64 $\pm$ 0.05 <sup>a</sup>
Week 3	0.34 $\pm$ 0.05 <sup>a</sup>	0.61 $\pm$ 0.08 <sup>a</sup>	0.54 $\pm$ 0.10 <sup>b</sup>	0.59 $\pm$ 0.07 <sup>b</sup>	0.47 $\pm$ 0.06 <sup>b</sup>
Week 4	0.36 $\pm$ 0.05 <sup>a</sup>	0.61 $\pm$ 0.10 <sup>a</sup>	0.44 $\pm$ 0.08 <sup>b</sup>	0.46 $\pm$ 0.06 <sup>b</sup>	0.43 $\pm$ 0.05 <sup>b</sup>
<i>p</i> -value	0.79	0.42	< .001	< .001	< .001
F-value	15.322	11.514	4.312	2.388	8.037

166 ANOVA, followed by Dunnet's multiple comparison test against week 1.

167 a= No significant difference at  $p < 0.05$ .

168 b= significantly different at  $p < 0.05$

169

170

171

172

173


174

175

176



177  
178  
179  
180  
181  
182  
183  
184  
185  
186  
187  
188  
189



190

191 **Fig. 4.1: Morphological Scores of the Rats according to Weeks**

192

193

194

195

196

197


198

199


200

201

202



**Group A**



**Group B**

Fig. 4.2: Histology of Femororbital Joints of Group A and Group B Rats (x400)

The joint cavity (JC) of arthritic control rats (Group B) was larger than the negative control rats (Group A), and had rough surfaces as well.

207

208

209


210

211


212

213

214



**Group C**



**Group B**

Fig. 4.3: Histology of Femororbital Joints of Group C and Group B Rats (x400)

216

217 The joint cavity (JC) of arthritic control rats (Group B) was larger than the negative  
218 control rats (Group C), and had rough surfaces as well.

219

220

221

222

223

224



225

226

227

228

229



### Group D



### Group B

231 Fig. 4.4: Histology of Femororbital Joints of Group D and Group B Rats (x400)

232 The joint cavity (JC) of arthritic control rats (Group B) was larger than the negative  
233 control rats (Group D), and had rough surfaces as well.

234

235



242

243

244

245 **Group E**

**Group B**

246

247 Fig. 4.5: Histology of Femororbital Joints of Group E and Group B Rats (x400)

248 The joint cavity (JC) of arthritic control rats (Group B) was larger than the negative  
249 control rats (Group E), and had rough surfaces as well.

250

251

252

## 253 **Discussion**

254 This study evaluated the anti-arthritic activity of a herbal formulation used in the treatment of  
255 rheumatoid arthritis in Nigeria. The result of the acute toxicity study on the herbal formulation  
256 indicates that it is safe and non-toxic at therapeutic doses. This result is consistent with an earlier  
257 work<sup>24</sup>, who evaluated the anti-inflammatory activity of Dazzle Capsule, another polyherbal  
258 formulation used in India.

259 There were significant reduction in the paw diameters of the rats treated with the herbal  
260 formulations. In rheumatoid arthritis, there is infiltration of the paw tissues by immune cells,  
261 chiefly neutrophils and macrophages. The reduction in the paw diameters may be due to  
262 inhibition of the infiltration by the herbal formulations<sup>25</sup> as well as inhibition of pannus  
263 formation and bone erosion<sup>26</sup>. This effect was comparable to that observed in the rats treated  
264 with the orthodox drug, Celebrex.

265 The levels of the inflammatory markers were significantly reduced in the groups treated with the  
266 herbal formulations, compared to the arthritic control group. This finding is probably due to the  
267 inhibitory effects of the herbal formulations on the production of inflammatory markers<sup>27</sup>. The  
268 anti-inflammatory effects of the herbal formulations were comparable with that observed with  
269 the orthodox drug.

270 Acute phase reactants such as C-reactive proteins are usually produced during inflammation such  
271 as in rheumatoid arthritis<sup>28</sup>. Also, immune cells, which are usually attracted to the inflamed  
272 synovium, produce TNF- $\alpha$ , IL-6 and other pro-inflammatory cytokines, and these contribute  
273 greatly to the pathology of rheumatoid arthritis<sup>29</sup>.

274 The combination therapy did not significantly reduce the parameters compared to the results  
275 obtained using the herbal drug alone or the orthodox drug alone.

276 Anti-arthritic herbal formulations can be used as effective therapeutic alternative for the  
277 management of rheumatoid arthritis. It may be necessary to consider them for integration into the  
278 regular health system.

279 **CONCLUSION:** The result indicated that the herbal formulation had anti-arthritic and anti-  
280 inflammatory potentials, comparable to that obtained by the use orthodox drug.

281

282 **CONFLICT OF INTEREST:** There was no conflict of interest.

283

284 **REFERENCES**

- 285 1.Choy, E. Understanding the Dynamics: Pathways Involved in the Pathogenesis of Rheumatoid  
286 Arthritis. *Rheumatology*, 2012; 51(5): 3-11.
- 287 2.Okoroiwu, I.L., Obeagu, E.I., Obeagu, G.U. Haematological variables in Rheumatoid Arthritis  
288 Patients in Imo State, Nigeria. *International Journal of Advanced Research in*  
289 *Biological Sciences*, 2016; 3(4): 91-98.
- 290 3.Gibofsky, A. Overview of Epidemiology, Pathophysiology, and Diagnosis of Rheumatoid  
291 Arthritis. *The American Journal of Managed Care*, 2012; 18: 295-302.
- 292 4.Yarwood, A., Huizinga, T.W.J., Worthington, J. The Genetics of Rheumatoid Arthritis: Risk  
293 and Protection in Different Stages of the Evolution of RA. *Rheumatology*, 2016;  
294 55(2): 199-209.
- 295 5.Kurko, J., Besenyei, T., Laki, J., Glant, T.T., Mickecz, K., Szekanecz, Z. Genetics of  
296 Rheumatoid Arthritis: A Comprehensive Review. *Clinical Reviews in Allergy &*  
297 *Immunology*, 2013; 45(2): 170-179.
- 298 6. de Vries, R. Genetics of Rheumatoid Arthritis: Time for a change. *Current Opinion of*  
299 *Rheumatology*, 2011; 23(3): 227-232.
- 300 7. Liao, K.P., Alfredsson, L., Karlson, E. W. Environmental Influences on Risk for Rheumatoid  
301 Arthritis. *Current Opinion in Rheumatology*, 2009; 21(3): 279-283.
- 302 8. Klareskog, L., Gregersen, P.K., Huizinga, T.W. Prevention of Autoimmune Rheumatic Disease:  
303 State of the Art and Future Perspectives. *Annals of Rheumatic Diseases*, 2010; 69:  
304 2062-2066.
- 305 9. World Health Organization (2008). Traditional Medicine.  
306 [www.who.int/medicentre/factsheet/fs134/en/index.html](http://www.who.int/medicentre/factsheet/fs134/en/index.html). Retrieved on 27th May,  
307 2018.
- 308 10. Carmona, F., Pereira, A.N.S. Herbal Medicines: Old and New Concepts, Truths and  
309 Misunderstandings. *Brasilian Journal of Pharmacognosy*, 2013; 23(2): 379-385.
- 310 11. Balasundaram, A., Kumari, A.R., John, G., Selvakumar, B.N. Antimicrobial Activity of the  
311 Leaf Extracts of Two Medicinal Plants Against MRSA from Human Urinary Tract  
312 Pathogens. *Research Journal of Microbiology*, 2011; 6: 625-631
- 313 12. Kalita, S., Kumar, G., Karthik, L., Rao, B.V. A Review on Medicinal Properties of Lantana  
314 camara Linn. *Research Journal of Pharmaceutical Technology*, 2012; 5: 711-715
- 315 13. Vieira, D.L.T. & Huang, S.M. Botanical-Drug Interactions: A Scientific Perspective. *Planta*  
316 *Medica*, 2012;78: 1400 – 1415.
- 317 14. Calitz, C., du Plessis, L., Gouws, C., Steyn, D, Steenekamp, J., Muller, C. & Hamman, S.  
318 Herbal Hepatotoxicity: Current Status, Examples and Challenges. *Expert Opinions*  
319 *Drug Metabolism and Toxicology*, 2015; 11: 1551 – 1565.
- 320 15. Philomena, G. Concerns regarding the Safety and Toxicity of Medicinal Plants-An  
321 Overview. *Journal of Applied Pharmaceutical Sciences*, 2011:1(6): 40-44.



- 322 16. Ekor, M. The Growing Use of Herbal Medicines: Issues Relating to Adverse Reactions and  
323 Challenges in Monitoring Safety. *Frontiers in pharmacology*, 2013; 4: 177-229.
- 324 17. Wadekar, J.B., Sawant, R.L., Patal, U.B. Rheumatoid Arthritis and Herbal Drugs: A Review.  
325 *The Journal of Phytopharmacology*, 2015; 4(6): 311-318.
- 326 18. Patel, M.K., Mandavia, D.R., Patel, T.K., Barvaliya, M.J. & Tripatti, C.B. Evaluation of Ant-  
327 inflammatory, Analgesic, and Antipyretic Effects of Ethanolic Extract of *Pedaliium*  
328 *Murex* Linn. Fruits. *African Journal of Traditional, Complementary and Alternative*  
329 *Medicine*, 2013;10(4): 94-100.
- 330 19. Paget, G. E. , Barnes, J. M. *Evaluation of Drug Activities*. In Lawrence, D. R. & Bacharach,  
331 A. L. (Eds.). *Pharmacometrics* (pp.161). New York: Academy Press, 1964.
- 332 20. Organization for Economic Cooperation and Development (2001).Guidance Document on  
333 Acute Oral Toxicity Testing.  
334 <https://ntp.niehs.nih.gov/iccvam/suppdocs/feddocus/oecd/oecd-gd24.pdf>. Retrieved on 23<sup>rd</sup>  
335 November, 2018.  
336
- 337 21. Foyet, H.S., Tsala, D.E., Zogo, J.C., Bodo, J.C.Z., Carine, A.N., Heroyne, L.T., Oben, E.K.  
338 Anti-inflammatory and Anti-arthritis Activity of a Methanol Extract from *Vitellaria*  
339 *paradoxa* Stem Bark. *Pharmacognosy Research*, 2015;7(4): 367-377
- 340 22. Hussein, S.Z., Mohd, Y.K., Makpol, S., Yusof, Y.A.M. Gelam Honey Inhibits the  
341 Production of Proinflammatory Mediators, NO, PGE2, TNF- $\alpha$  and IL-6 in  
342 Carrageenan-induced Acute Paw Edema in Rats. *Evidence-based Complementary and*  
343 *Alternative Medicine*, 2012, <http://dx.doi.org/10.1155/109636>
- 344 23. Vijayalaxmi, A., Bakshi, U., Begum, N., Kowmudi, V., Naveen, K.Y., Reddy, Y. Anti-  
345 arthritic and Anti-inflammatory Activity of Beta-Caryophyllene against Freund's  
346 Complete Adjuvant Induced Arthritis in Wister Rats. *Journal of Bone Reports &*  
347 *Recommendations*, 2015;1(29): 1-10.
- 348 24. Surendra, B., Hardik, S., Bijal, S., Mayanik, A., Rakesh, P. Evaluation of Polyherbal  
349 Formulation for Anti-inflammatory Activity in Carrageenan-induced Paw Oedema Model  
350 in Rats. *International Journal of Research in Ayurveda Pharmacology*, 2013;4(2): 145-  
351 148.
- 352 25. Nargarkar, B., Jagtap, S. Effect of New Polyherbal Formulations DF1911, DF2112 and  
353 DF2813 on CFA-induced Inflammation in Rat Model. *BMC Complementary and*  
354 *Alternative Medicine*, 2017;17: 194
- 355 26. Bhatt, L., Maithani, S. Protective Effect of a Polyherbal Formulation, Freemodex, against  
356 Acute Models of Pain, Inflammation, Arthritis and Immunosuppression. *International*  
357 *Journal of Nutrition, Pharmacology and Neurological Science*, 2017; 7: 88-93.
- 358 27. Mahdi, H.J., Khan, N. A.K., Asmawi, M.Z.B., Mahmud, R., Murugaiyah, V.A. In vivo Anti-  
359 arthritic and Antinociceptive Effects of Ethanol Extracts of *Moringa oleifera* Leaves on  
360 Complete Freund's Adjuvant-induced Arthritis in Rats. *Integrative Medical Research*,  
361 2018; 7(1): 85-94

- 362 28. Jain, S., Gautam, V. ,Naseem, S. Acute-phase Proteins: As Diagnostic Tools. *Journal of*  
363 *Pharmacy and BioAllied Sciences*, 2011; 3(1): 118-127.
- 364 29. Alghasham, A., Rasheed, Z. Therapeutic Targets for Rheumatoid Arthritis: Progress and  
365 promises. *Autoimmunity*, 2014; 47(2): 77-94.

UNDER PEER REVIEW